Back to search

National and Kapodistrian University of Athens

Έλεγχος της έκφρασης του υποδοχέα PD-L1 σε θηλώδη καρκινώματα θυρεοειδούς αδένα, διερεύνηση της μεταξύ τους σχέσης και της χρήσης του ως διαγνωστικό και προγνωστικό δείκτη

Abstract

dc:description

Background: Programmed cell death ligand 1 (PD-L1) expression is a well-established prerequisite for the use of immune checkpoint inhibitors and is increasingly recognized as a prognostic biomarker in various malignancies. However, its prognostic significance in thyroid cancer (TC), particularly papillary thyroid carcinoma (PTC), remains largely unexplored and somewhat controversial, with findings to date being limited and inconsistent. The aim of this study was to evaluate PD-L1 expression in a well-characterized cohort of patients with PTC and assess its association with key clinicopathological features and clinical outcomes. Materials and Methods: This retrospective, single-center cohort study included patients with histologically confirmed PTC who underwent thyroid surgery at the “Korgialeneio – Benakeio” General Hospital of Athens in Greece between 2007 and 2018. Formalin-fixed, paraffin-embedded (FFPE) tumor samples were assessed for PD-L1 expression using immunohistochemistry and scored using the combined positive score (CPS), with CPS ≥10 indicating PD-L1 positivity. Clinicopathological data were collected through review of patients’ medical records and postoperative histopathology reports, and associations with PD-L1 status were analyzed. Disease-free recurrence (DFS) and overall survival (OS) were also evaluated using Kaplan–Meier methods. Results: Among 81 PTC patients included in this study (median age: 48 years, 83% female), PD-L1 positivity (CPS ≥10) was observed in 45.7%. CPS ≥10 status was significantly associated with larger tumor size, higher pT stage (pT3–pT4), extrathyroidal extension, lymph node metastasis, and the presence of aggressive histologic variants. Coexisting Hashimoto’s thyroiditis and higher rates of radioactive iodine therapy (RAI) were also more common in the PD-L1–positive group. At a median follow-up of 9 years, the overall recurrence rate was 8.6%, with significantly higher recurrence and shorter DFS among patients with CPS ≥10 tumors. OS remained high across both groups. Conclusions: PD-L1 expression was present in nearly half of this real-world Greek PTC cohort and was associated with multiple adverse clinicopathological features and an increased risk of recurrence. These findings support the potential utility of PD-L1 as a prognostic biomarker in PTC and may inform postoperative risk stratification and follow-up strategies.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Spyroulia, Dimitra
  • Σπυρούλια, Δήμητρα

Subjects

dc:subject × 22

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60177

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Spyroulia, Dimitra; Σπυρούλια, Δήμητρα. Έλεγχος της έκφρασης του υποδοχέα PD-L1 σε θηλώδη καρκινώματα θυρεοειδούς αδένα, διερεύνηση της μεταξύ τους σχέσης και της χρήσης του ως διαγνωστικό και προγνωστικό δείκτη. National and Kapodistrian University of Athens, 2025. http://hdl.handle.net/10442/hedi/60177